Navigation Links
Genomic Health Announces Oncotype DX(R) Provides Additional Prognostic Benefit in Patients Assessed With Adjuvant Online
Date:12/15/2007

udy found that the Recurrence Score result was a highly significant predictor of recurrence in both node-negative disease (p=0.0007) and node-positive disease (p=0.0004). In addition, a low Recurrence Score result predicted a low likelihood of recurrence regardless of nodal status.

"In examining the relationship between the Oncotype DX Recurrence Score and Adjuvant Online, we found that both tools have value in providing crucial information on the likelihood of breast cancer recurrence," said Peter Ravdin, M.D., Ph.D., the M.D. Anderson Cancer Center physician who developed the Adjuvant Online tool and a co-author of the study. "Specifically, the addition of Oncotype DX Recurrence Score results yielded supplementary insight on outcomes for breast cancer patients. Used together, we have the opportunity to more effectively guide personal treatment decisions based on a woman's individual breast cancer."

About Oncotype DX(R)

Oncotype DX is the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of breast cancer recurrence, the likelihood of breast cancer survival and the likelihood of chemotherapy benefit. Oncotype DX has been extensively evaluated in multiple independent studies involving more than 3,300 breast cancer patients, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, nearly 7,000 physicians have ordered more than 40,000 tests, and health plans covering over 50 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. The American Society of Clinical Oncologists (ASCO) recommends the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please vi
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Daily Gossip reveals in its review that the Flat Belly ... loss tips. , The author of the new method ... to implement. Users don’t have to worry, as they will ... counting calories. , The Flat Belly Forever program was ... weeks weight loss program to help sufferers model the perfect ...
(Date:7/31/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... at 10 tips to help drug or alcohol addicts cope ... process, and one that former addicts and those who support ... Drug Rehabilitation’s CEO Per Wickstrom . , According ...
(Date:7/31/2014)... The study, The Truth Behind ... episode of care payments for four clinical areas—congestive heart ... replacements (hips and knees). Using the definition of ... Care Improvement program, the study examines these clinical areas ... the country. , “Our study reaffirms that, in most ...
(Date:7/30/2014)... 30, 2014 The Mesothelioma ... Penn's Abramson Cancer Center, will host a regional ... experts in the field of mesothelioma. September 26 marks ... is open to the public, and specifically aimed at ... who have been exposed to asbestos. , The conference ...
(Date:7/30/2014)... events experienced during deployment, returning National Guard soldiers ... if faced with civilian life setbacks, including job ... legal problemsall commonplace in military families. Results of ... School of Public Health are published online in ... , Alcohol abuse is a major concern for ...
Breaking Medicine News(10 mins):Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3Health News:Vets' alcohol problems linked to stress on the home front 2
... Company (NYSE: PG ) announced net sales growth of ... Organic sales were up five,percent, delivering at the mid-point of ... led by strong growth in the Beauty, Fabric,Care & Home ... earnings,per share increased 12 percent to $1.03 for the quarter., ...
... /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, Inc. (the "Company") ... device company that develops, manufactures and markets ... it will be attending the,Credit Suisse Asian ... Location: Beijing, China, China Medical ...
... Melting Pot Restaurants join,St. Jude Children,s Research Hospital in ... - Dec. 31 to "give thanks for the healthy ... not.", "From the beginning, our involvement with St. ... said Kendra Sartor, vice president,of brand development for The ...
... growth, the global fluoroscopy and mobile C-arms market is forecast to ... form a large chunk of total market, particularly in the developed ... Asia-Pacific. , ... San Jose, CA (PRWEB) October 29, ...
... campaign against the threat of Coronary Heart Disease joined by Royle Family ... ... Tomlinson has warned British men against the threat of Coronary Heart Disease ... that he did not take his heart health seriously in the past ...
... 28 Today the ... responded to a request ... to hold an unnecessary,debate., ... letters, please visit:, http://www.noonprop8.com/downloads/FSchubert102808.pdf ...
Cached Medicine News:Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 2Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 3Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 4Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 5Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 6Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 7Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 8Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 9Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 10Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 11Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 12Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 13Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 14Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 15Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 16Health News:P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth 17Health News:The Melting Pot Joins St. Jude Children's Research Hospital(R) for the Fifth Annual Thanks and Giving(R) Campaign 2Health News:The Melting Pot Joins St. Jude Children's Research Hospital(R) for the Fifth Annual Thanks and Giving(R) Campaign 3Health News:Fluoroscopy and Mobile C-arms Unit Sales to Reach 9.6 Thousand Units by 2012, According to New Report by Global Industry Analysts 2Health News:Fluoroscopy and Mobile C-arms Unit Sales to Reach 9.6 Thousand Units by 2012, According to New Report by Global Industry Analysts 3Health News:Ricky Tomlinson Joins Lloydspharmacy Against Coronary Heart Disease 2Health News:Ricky Tomlinson Joins Lloydspharmacy Against Coronary Heart Disease 3
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... NEW YORK , July 30, 2014 ... of new products for oncology supportive care, announced that ... has been featured in an article on OncLive.com titled, ... Head and Neck Cancers."  Dr. Steve Sonis , ... the growing demand seen in the oncology community for ...
(Date:7/30/2014)... July 30, 2014 /PRNewswire-iReach/ -- This is a ... Chinese Heparin sodium (CAS 9041-08-1) & calcium (CAS ... information of Heparin sodium (CAS 9041-08-1) & calcium ... technology. The report then explores global and China,s ... calcium (CAS 37270-89-6) listing their product specification, capacity, ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5
... System provides anterior column support for single ... T1 to L5. The system consists of ... cages that are stacked to a desired ... Carbon Fiber Reinforced Polymer material emulates the ...
... provides anterior column support for single or ... to L5. The system consists of one ... that are stacked to a desired height, ... Fiber Reinforced Polymer material emulates the biomechanical ...
... Cage system is a carbon fiber reinforced ... and biologic functions of posterior lumbar interbody ... provides a device designed to meet the ... cancellous bone, the best possible bone for ...
... is highly adaptable and therefore suitable for ... to its extraordinary small outer diameter and ... of a simple but secure and reliable ... steering instruments around the corner. These characteristics ...
Medicine Products: